PE20001421A1 - Sulfonamidas heterociclicas como inhibidores de endotelina - Google Patents
Sulfonamidas heterociclicas como inhibidores de endotelinaInfo
- Publication number
- PE20001421A1 PE20001421A1 PE2000000025A PE0000252000A PE20001421A1 PE 20001421 A1 PE20001421 A1 PE 20001421A1 PE 2000000025 A PE2000000025 A PE 2000000025A PE 0000252000 A PE0000252000 A PE 0000252000A PE 20001421 A1 PE20001421 A1 PE 20001421A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pyridin
- metoxy
- methyl
- compounds
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title abstract 2
- 108050009340 Endothelin Proteins 0.000 title abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- -1 PYRROLYL Chemical class 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- HXURYNQXMBRJLU-UHFFFAOYSA-N 5-methylpyridine-2-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)N=C1 HXURYNQXMBRJLU-UHFFFAOYSA-N 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001409 amidines Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical class O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 230000006442 vascular tone Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A SULFONAMIDAS HETEROCICLICAS DE FORMULA I, DONDE: R1 ES PIRIDILO, PIRROLILO, IMIDAZOLILO, TIAZOLILO, TIAZOLINILO, OXAZOLILO; R2 ES R21, -Y-R22, HETEROCICLO CON OH, ALQUENILO, AMINO, ALCANOILAMINO, ALCOXICARBONILAMINO, ENTRE OTROS; R21 ES CIANO, HIDROXI-ALQUILO, CARBOXI, -C(O)NRaRb, -(CH2)(1-4)NHRc, (CH2)(1-4)NHCONH(CH2)(0-3)CH3, AMIDINO, HIDROXIAMIDINO, ALCOXICARBONILO, ENTRE OTROS; R22 ES H, ALCANOILO, CARBOXIALQUILO, ALCOXICARBONILO, ALCOXICARBONILO-ALQUILO, CARBAMOIL-ALQUILO, ENTRE OTROS; Ra ES H, ALQUILO SUSTITUIDO CON OH, ALCOXI; Rb ES H, ALQUILO; Rc ES H, ACETILO, ALQUILSULFONILO; X ES CH, N; Y ES O, NH. SON COMPUESTOS PREFERIDOS ACIDO 4-[4-METOXI-5-(2-METOXI-FENOXI)-6-(5-METIL-PIRIDIN-2-SULFONILAMINO)-PIRIMIDIN-2-IL]-PIRIDIN-2-CARBOXILICO, ESTER METILICO DEL ACIDO 4-[-4-METOXI-5-(2-METOXI-FENOXI)-6-(5-METIL-PIRIDIN-2-SULFONILAMINO)-PIRIMIDIN-2-IL]-PIRIDIN-2-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION; A COMPUESTOS INTERMEDIOS Y A UNA COMPOSICION QUE COMPRENDE ADEMAS ANTIHIPERTENSIVOS, ANTIARRITMICOS, ANTIANGINOSOS, ANTITROMBOTICOS, REDUCTORES DE LIPIDOS, ANTIOXIDANTES. LOS COMPUESTOS DE FORMULA I SON INHIBIDORES DE ENDOTELINA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL TONO VASCULAR ANORMAL Y LA DISFUNCION ENDOTELIAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99100784 | 1999-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001421A1 true PE20001421A1 (es) | 2000-12-18 |
Family
ID=8237359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000025A PE20001421A1 (es) | 1999-01-18 | 2000-01-13 | Sulfonamidas heterociclicas como inhibidores de endotelina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6242601B1 (es) |
| EP (1) | EP1149091B1 (es) |
| JP (1) | JP3983477B2 (es) |
| KR (1) | KR100478797B1 (es) |
| CN (1) | CN1340049A (es) |
| AR (1) | AR029879A1 (es) |
| AT (1) | ATE389648T1 (es) |
| AU (1) | AU763112B2 (es) |
| BR (1) | BR0007595A (es) |
| CA (1) | CA2359363C (es) |
| CO (1) | CO5150187A1 (es) |
| CZ (1) | CZ20012546A3 (es) |
| DE (1) | DE60038365D1 (es) |
| ES (1) | ES2301476T3 (es) |
| GC (1) | GC0000248A (es) |
| HR (1) | HRP20010515A2 (es) |
| HU (1) | HUP0200021A3 (es) |
| IL (2) | IL144055A0 (es) |
| MA (1) | MA27124A1 (es) |
| MY (1) | MY121136A (es) |
| NO (1) | NO322800B1 (es) |
| NZ (1) | NZ512662A (es) |
| PE (1) | PE20001421A1 (es) |
| PL (1) | PL350093A1 (es) |
| RU (1) | RU2224757C2 (es) |
| TR (1) | TR200102071T2 (es) |
| TW (1) | TWI284642B (es) |
| UY (1) | UY25904A1 (es) |
| WO (1) | WO2000042035A1 (es) |
| YU (1) | YU50001A (es) |
| ZA (1) | ZA200105279B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7351834B1 (en) * | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
| MY140724A (en) | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
| WO2002053557A1 (en) * | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| ES2400070T3 (es) * | 2001-12-03 | 2013-04-05 | Bayer Healthcare Llc | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos |
| WO2003068229A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| ATE529406T1 (de) * | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| AU2003285321B2 (en) * | 2002-12-02 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| US7269460B2 (en) * | 2003-02-28 | 2007-09-11 | Medtronic, Inc. | Method and apparatus for evaluating and optimizing ventricular synchronization |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| HRP20060073B1 (hr) | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| EP1595880A1 (en) * | 2004-05-13 | 2005-11-16 | Speedel Pharma AG | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| RU2435585C2 (ru) * | 2006-04-13 | 2011-12-10 | Актелион Фармасьютиклз Лтд | Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких |
| AU2007267209A1 (en) | 2006-05-29 | 2007-12-06 | Nicox S.A. | Nitrated heterocyclic compounds as endothelin receptor antagonist |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| EP3750884B1 (en) * | 2014-11-21 | 2022-03-30 | Daikin Industries, Ltd. | Novel fluorinated unsaturated cyclic carbonate and process for producing the same |
| CN109260164A (zh) * | 2018-10-07 | 2019-01-25 | 威海贯标信息科技有限公司 | 一种阿伏生坦片剂组合物 |
| CN112898208B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用 |
| CN112778215B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用 |
| TW202329952A (zh) | 2021-12-17 | 2023-08-01 | 瑞士商愛杜西亞製藥有限公司 | 克拉生坦(clazosentan)二鈉鹽之製備方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837708A (en) | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
| WO1996016963A1 (de) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
| CA2162630C (en) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
| TW313568B (es) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| ATE201202T1 (de) * | 1995-12-20 | 2001-06-15 | Yamanouchi Pharma Co Ltd | Arylethensulfonamid-derivate und diese enthaltende medikamente |
-
2000
- 2000-01-07 TW TW089100181A patent/TWI284642B/zh not_active IP Right Cessation
- 2000-01-10 WO PCT/EP2000/000103 patent/WO2000042035A1/en not_active Ceased
- 2000-01-10 TR TR2001/02071T patent/TR200102071T2/xx unknown
- 2000-01-10 DE DE60038365T patent/DE60038365D1/de not_active Expired - Lifetime
- 2000-01-10 AU AU26630/00A patent/AU763112B2/en not_active Ceased
- 2000-01-10 EP EP00904889A patent/EP1149091B1/en not_active Expired - Lifetime
- 2000-01-10 RU RU2001122114/04A patent/RU2224757C2/ru not_active IP Right Cessation
- 2000-01-10 CZ CZ20012546A patent/CZ20012546A3/cs unknown
- 2000-01-10 ES ES00904889T patent/ES2301476T3/es not_active Expired - Lifetime
- 2000-01-10 AT AT00904889T patent/ATE389648T1/de not_active IP Right Cessation
- 2000-01-10 KR KR10-2001-7008996A patent/KR100478797B1/ko not_active Expired - Fee Related
- 2000-01-10 PL PL00350093A patent/PL350093A1/xx not_active Application Discontinuation
- 2000-01-10 IL IL14405500A patent/IL144055A0/xx not_active IP Right Cessation
- 2000-01-10 BR BR0007595-7A patent/BR0007595A/pt not_active Application Discontinuation
- 2000-01-10 YU YU50001A patent/YU50001A/sh unknown
- 2000-01-10 CA CA002359363A patent/CA2359363C/en not_active Expired - Fee Related
- 2000-01-10 HR HR20010515A patent/HRP20010515A2/hr not_active Application Discontinuation
- 2000-01-10 JP JP2000593603A patent/JP3983477B2/ja not_active Expired - Lifetime
- 2000-01-10 NZ NZ512662A patent/NZ512662A/en unknown
- 2000-01-10 HU HU0200021A patent/HUP0200021A3/hu unknown
- 2000-01-10 CN CN00803754A patent/CN1340049A/zh active Pending
- 2000-01-13 PE PE2000000025A patent/PE20001421A1/es not_active Application Discontinuation
- 2000-01-13 US US09/482,810 patent/US6242601B1/en not_active Expired - Fee Related
- 2000-01-14 AR ARP000100159A patent/AR029879A1/es unknown
- 2000-01-14 CO CO00001821A patent/CO5150187A1/es unknown
- 2000-01-14 UY UY25904A patent/UY25904A1/es unknown
- 2000-01-14 MY MYPI20000124A patent/MY121136A/en unknown
- 2000-01-17 GC GCP2000481 patent/GC0000248A/en active
-
2001
- 2001-06-26 ZA ZA200105279A patent/ZA200105279B/en unknown
- 2001-06-28 IL IL144055A patent/IL144055A/en unknown
- 2001-07-12 NO NO20013454A patent/NO322800B1/no unknown
- 2001-07-17 MA MA26270A patent/MA27124A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001421A1 (es) | Sulfonamidas heterociclicas como inhibidores de endotelina | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| TW346485B (en) | Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents | |
| PE20040512A1 (es) | Compuesto de pirazol-pirimidina anilina | |
| ES2182485T3 (es) | Derivados de aminofenil isosazolina sustituidos utiles como agentes antimicrobianos. | |
| NO327427B1 (no) | Indolylmaleimidderivater, farmasoytiske sammensetninger samt anvendelser av slike. | |
| UY24257A1 (es) | Derivados de pirimidinodiona, piridinotriona, triazinodiona como antagonistas del receptor adrenérgico alfa-1. | |
| PE20040680A1 (es) | Inhibidores novedosos de cinasas | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| PE20060010A1 (es) | 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| PE20040526A1 (es) | Amidas de 4-alquenil piperidina de indol, azaindol y relacionadas con heterociclicos | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE1998A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
| AR022019A1 (es) | Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20040267A1 (es) | Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas | |
| NZ513594A (en) | Heterocyclic compounds, intermediates thereof and elastase inhibitors | |
| US5308844A (en) | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones and their use in therapy | |
| EP0655057A1 (en) | CYANOGUANIDINE AS A POTASS CHANNEL BLOCKER. | |
| AR044720A1 (es) | Una sulfonamida heterociclica, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, y compuestos utiles como intermediari0s | |
| ATE121294T1 (de) | Indanderivate. | |
| WO2008128832A1 (en) | Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome | |
| CA2388470A1 (en) | Use of carbonylamino derivatives against cns disorders | |
| CA2422807A1 (en) | N-substituted benzothiophenesulfonamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |